CL2021001330A1 - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CL2021001330A1 CL2021001330A1 CL2021001330A CL2021001330A CL2021001330A1 CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1 CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A CL2021001330 A CL 2021001330A CL 2021001330 A1 CL2021001330 A1 CL 2021001330A1
- Authority
- CL
- Chile
- Prior art keywords
- heterocyclic compounds
- compounds
- new heterocyclic
- new
- processes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención proporciona nuevos compuestos heterocíclicos que tienen la fórmula general (I): en donde A, B, L, X, R1, R2, R3 y R4 son, como se describen en la presente, composiciones que incluyen los compuestos, procesos para elaborar los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18207725 | 2018-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021001330A1 true CL2021001330A1 (es) | 2021-10-29 |
Family
ID=64453331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021001330A CL2021001330A1 (es) | 2018-11-22 | 2021-05-20 | Nuevos compuestos heterocíclicos |
Country Status (31)
Country | Link |
---|---|
US (1) | US20210387999A1 (es) |
EP (1) | EP3883936B1 (es) |
JP (1) | JP7444882B2 (es) |
KR (1) | KR20210094540A (es) |
CN (1) | CN113166170A (es) |
AR (1) | AR117139A1 (es) |
AU (1) | AU2019383500A1 (es) |
BR (1) | BR112021009348A2 (es) |
CA (1) | CA3119506A1 (es) |
CL (1) | CL2021001330A1 (es) |
CO (1) | CO2021007056A2 (es) |
CR (1) | CR20210247A (es) |
DK (1) | DK3883936T3 (es) |
ES (1) | ES2955037T3 (es) |
FI (1) | FI3883936T3 (es) |
HR (1) | HRP20231083T1 (es) |
HU (1) | HUE062913T2 (es) |
IL (1) | IL283333B2 (es) |
LT (1) | LT3883936T (es) |
MA (1) | MA55131B1 (es) |
MX (1) | MX2021005714A (es) |
PE (1) | PE20211870A1 (es) |
PH (1) | PH12021551167A1 (es) |
PL (1) | PL3883936T3 (es) |
PT (1) | PT3883936T (es) |
RS (1) | RS64579B1 (es) |
SG (1) | SG11202104206SA (es) |
SI (1) | SI3883936T1 (es) |
TW (1) | TWI825227B (es) |
UA (1) | UA128505C2 (es) |
WO (1) | WO2020104494A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
WO2019105915A1 (en) | 2017-11-28 | 2019-06-06 | F. Hoffmann-La Roche Ag | New heterocyclic compounds |
EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
DK3837263T3 (da) | 2018-08-13 | 2024-09-09 | Hoffmann La Roche | Nye heterocykliske forbindelser som monoacylglycerollipasehæmmere |
US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
WO2022049134A1 (en) | 2020-09-03 | 2022-03-10 | F. Hoffmann-La Roche Ag | Heterocyclic compounds |
JP2023542908A (ja) * | 2020-09-18 | 2023-10-12 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | カルボニル複素環系化合物及びその使用 |
KR20230142745A (ko) | 2021-01-29 | 2023-10-11 | 세딜라 테라퓨틱스, 인크. | Cdk2 억제제 및 그의 사용 방법 |
MX2023015436A (es) | 2021-06-26 | 2024-02-21 | Cedilla Therapeutics Inc | Inhibidores de cdk2 y metodos de uso de los mismos. |
WO2023130043A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment of anxiety |
WO2023130050A1 (en) * | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Monoacylglycerol lipase inhibitors and use thereof for the treatment and management of pain |
AR128333A1 (es) * | 2022-01-25 | 2024-04-17 | Hoffmann La Roche | Nuevos compuestos heterociclicos |
WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
TW202415666A (zh) | 2022-08-08 | 2024-04-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
WO2024033479A1 (en) * | 2022-08-11 | 2024-02-15 | Remynd N.V. | (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders |
WO2024061853A1 (en) * | 2022-09-20 | 2024-03-28 | F. Hoffmann-La Roche Ag | Fluorescent probes for magl |
TW202428574A (zh) * | 2022-10-24 | 2024-07-16 | 瑞士商赫孚孟拉羅股份公司 | 新穎雜環化合物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
CA2773182A1 (en) | 2009-09-10 | 2011-03-17 | F. Hoffmann-La Roche Ag | Inhibitors of jak |
WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
JP5990297B2 (ja) | 2015-03-03 | 2016-09-14 | タイヨーエレック株式会社 | 遊技機 |
JP6653319B2 (ja) * | 2015-03-30 | 2020-02-26 | 武田薬品工業株式会社 | 複素環化合物 |
CN107849015B (zh) | 2015-05-21 | 2021-03-19 | 葛兰素知识产权发展有限公司 | 作为pad4抑制剂的苯并咪唑衍生物 |
CN107849017B (zh) | 2015-07-31 | 2021-03-30 | 辉瑞公司 | 作为magl抑制剂的1,1,1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1,1,1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物 |
US10385057B2 (en) * | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
-
2019
- 2019-11-20 AU AU2019383500A patent/AU2019383500A1/en active Pending
- 2019-11-20 MA MA55131A patent/MA55131B1/fr unknown
- 2019-11-20 JP JP2021528972A patent/JP7444882B2/ja active Active
- 2019-11-20 HR HRP20231083TT patent/HRP20231083T1/hr unknown
- 2019-11-20 IL IL283333A patent/IL283333B2/en unknown
- 2019-11-20 MX MX2021005714A patent/MX2021005714A/es unknown
- 2019-11-20 PL PL19809026.8T patent/PL3883936T3/pl unknown
- 2019-11-20 PE PE2021000714A patent/PE20211870A1/es unknown
- 2019-11-20 CA CA3119506A patent/CA3119506A1/en active Pending
- 2019-11-20 RS RS20230788A patent/RS64579B1/sr unknown
- 2019-11-20 ES ES19809026T patent/ES2955037T3/es active Active
- 2019-11-20 HU HUE19809026A patent/HUE062913T2/hu unknown
- 2019-11-20 FI FIEP19809026.8T patent/FI3883936T3/fi active
- 2019-11-20 WO PCT/EP2019/081870 patent/WO2020104494A1/en active Application Filing
- 2019-11-20 DK DK19809026.8T patent/DK3883936T3/da active
- 2019-11-20 UA UAA202103201A patent/UA128505C2/uk unknown
- 2019-11-20 SG SG11202104206SA patent/SG11202104206SA/en unknown
- 2019-11-20 BR BR112021009348-6A patent/BR112021009348A2/pt unknown
- 2019-11-20 SI SI201930619T patent/SI3883936T1/sl unknown
- 2019-11-20 PT PT198090268T patent/PT3883936T/pt unknown
- 2019-11-20 CR CR20210247A patent/CR20210247A/es unknown
- 2019-11-20 KR KR1020217015287A patent/KR20210094540A/ko unknown
- 2019-11-20 CN CN201980077284.5A patent/CN113166170A/zh active Pending
- 2019-11-20 LT LTEPPCT/EP2019/081870T patent/LT3883936T/lt unknown
- 2019-11-20 EP EP19809026.8A patent/EP3883936B1/en active Active
- 2019-11-21 AR ARP190103417A patent/AR117139A1/es unknown
- 2019-11-21 TW TW108142267A patent/TWI825227B/zh active
-
2021
- 2021-05-20 CL CL2021001330A patent/CL2021001330A1/es unknown
- 2021-05-20 US US17/325,934 patent/US20210387999A1/en active Pending
- 2021-05-21 PH PH12021551167A patent/PH12021551167A1/en unknown
- 2021-05-28 CO CONC2021/0007056A patent/CO2021007056A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
CO2021002382A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
CL2021000361A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
CL2023000594A1 (es) | Compuestos heterocíclicos | |
CO2020009567A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) de oxazina | |
DOP2017000267A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
CO2023014721A2 (es) | Compuestos heterocíclicos | |
CO2022002000A2 (es) | Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl) | |
CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
UY37487A (es) | Amidas heterocíclicas como inhibidores de quinasa | |
CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
CO2022002336A2 (es) | Compuestos heterocíclicos | |
CR20180363A (es) | Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
CO2022002339A2 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
CO2017008600A2 (es) | Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos | |
BR112013018732A2 (pt) | novos derivados de amida de aril-benzocicloalquila | |
CR20170496A (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
CL2022000556A1 (es) | Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de magl | |
CO2022003062A2 (es) | Compuestos heterocíclicos | |
CO2023016204A2 (es) | Inhibidores de nlrp3 | |
CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
CO2023010212A2 (es) | Derivados novedosos de pirimidin-2-il sulfonamida | |
CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 |